AbbVie Inc. (ABBV)
AbbVie Stock Rises 16% Year to Date: Time to Buy, Sell or Hold?
Those who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth in 2025.
Trump's tariffs are a new challenge for Big Pharma. Here are the best positioned stocks
Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are 'underappreciated.'
Best Dividend Aristocrats For April 2025
Dividend Aristocrats are outperforming the S&P 500 in 2025, demonstrating resilience, with NOBL up 1.78% YTD versus SPY's 4.9% decline. Top performers include Consolidated Edison (+22.98%), Brown & Brown (+20.65%), and AbbVie (+16.61%), showcasing strong double-digit gains. 29 out of 69 Dividend Aristocrats have announced dividend increases in 2025, with an average growth rate of 4.15%.
AbbVie: Margin Expansion Potential Can Support Elevated P/E
I don't see an obvious bias in AbbVie Inc.'s risk/return ratio. But I see it as a solid hold under current conditions. The company is grappling with diminishing Humira sales and is also trading at an above-average P/E. However, I see a potential profit margin expansion and also a healthy EPS growth ahead due to many catalysts.
Want $1 Million in Retirement? 3 Stocks to Buy Now and Hold for Decades.
Building a retirement portfolio of $1 million or more is within reach for many Americans. The primary things you'll need are time and money to invest.
Top 4 defensive stocks to buy and hold ahead of Liberation Day
American stocks have crashed this year as concerns about Donald Trump tariffs rose. The top blue-chip indices like the Dow Jones, Nasdaq 100, and S&P 500 have all moved into a correction as recession odds have soared.
3 Relatively Safe Stocks to Buy Right Now
Investing in stocks comes with risks. There's no way around that fact.
AbbVie Vs. Sanofi: Which Is The Better Investment Right Now
AbbVie and Sanofi occupy leading positions in the global immunology market. Each of them has advantages, as well as dark spots in the pipeline of drugs relative to the rival. In this article you will discover whether Sanofi or AbbVie is a more promising stock in the long term.
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
2 Dividend Stocks Defying the Market Dip to Buy for a Lifetime of Passive Income
Equities haven't performed well this year due to a combination of factors. Macroeconomic tensions are at the top of that list.
AbbVie (ABBV) Stock Sinks As Market Gains: Here's Why
The latest trading day saw AbbVie (ABBV) settling at $209.17, representing a -0.4% change from its previous close.
